Revance Therapeutics, Inc.
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II cli… Read more
Revance Therapeutics, Inc. (RVNC) - Total Assets
Latest total assets as of September 2024: $461.56 Million USD
Based on the latest financial reports, Revance Therapeutics, Inc. (RVNC) holds total assets worth $461.56 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Revance Therapeutics, Inc. - Total Assets Trend (2011–2023)
This chart illustrates how Revance Therapeutics, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Revance Therapeutics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2023)
Revance Therapeutics, Inc.'s total assets of $461.56 Million consist of 70.8% current assets and 29.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.7% |
| Accounts Receivable | $27.68 Million | 5.8% |
| Inventory | $45.58 Million | 9.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $9.81 Million | 2.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2023)
This chart illustrates how Revance Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Revance Therapeutics, Inc.'s current assets represent 70.8% of total assets in 2023, a decrease from 75.4% in 2011.
- Cash Position: Cash and equivalents constituted 28.7% of total assets in 2023, down from 74.2% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 9.5% of total assets.
Revance Therapeutics, Inc. Competitors by Total Assets
Key competitors of Revance Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Revance Therapeutics, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Revance Therapeutics, Inc. generates 0.49x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Revance Therapeutics, Inc. is currently not profitable relative to its asset base.
Revance Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.12 | 4.73 | 7.24 |
| Quick Ratio | 3.05 | 4.17 | 7.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $249.64 Million | $ 306.36 Million | $ 255.62 Million |
Revance Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Revance Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.30 |
| Latest Market Cap to Assets Ratio | 0.70 |
| Asset Growth Rate (YoY) | -17.8% |
| Total Assets | $478.45 Million |
| Market Capitalization | $333.19 Million USD |
Valuation Analysis
Below Book Valuation: The market values Revance Therapeutics, Inc.'s assets below their book value (0.70 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Revance Therapeutics, Inc.'s assets decreased by 17.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Revance Therapeutics, Inc. (2011–2023)
The table below shows the annual total assets of Revance Therapeutics, Inc. from 2011 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $478.45 Million | -17.78% |
| 2022-12-31 | $581.90 Million | +9.55% |
| 2021-12-31 | $531.16 Million | -26.25% |
| 2020-12-31 | $720.22 Million | +111.65% |
| 2019-12-31 | $340.29 Million | +50.34% |
| 2018-12-31 | $226.35 Million | -23.45% |
| 2017-12-31 | $295.70 Million | +44.70% |
| 2016-12-31 | $204.36 Million | -25.91% |
| 2015-12-31 | $275.82 Million | +43.31% |
| 2014-12-31 | $192.47 Million | +749.94% |
| 2013-12-31 | $22.64 Million | +68.70% |
| 2012-12-31 | $13.42 Million | -66.38% |
| 2011-12-31 | $39.93 Million | -- |